Clinical Trials

NCT06065748 | RECRUITING | PHASE3
1050 participants

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-05
Start Date:
2023-12-11
Completion:
2027-02-19
Conditions
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions
  • DRUG
  • DIAGNOSTIC_TEST
No Results Yet
NCT06001749 | RECRUITING | PHASE2
15 participants

Psilocybin in Cancer Pain Study

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-05
Start Date:
2024-09-23
Completion:
2026-10-01
Conditions
  • Opioid-Related Disorders
  • Pain Management
  • Pain Management and Care
  • Advanced Cancer
  • Advanced Cancers
Interventions
  • DRUG
No Results Yet
NCT05943626 | RECRUITING | NA
20 participants

Circadian Intervention to Improve Cardiometabolic Health

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-05
Start Date:
2023-06-13
Completion:
2026-12-31
Conditions
  • Cardiometabolic Syndrome
  • Type 2 Diabetes
  • Sleep
  • Time Restricted Feeding
  • Lifestyle Factors
  • Overweight and Obesity
  • Insulin Sensitivity
  • Eating Habit
  • Sleep Hygiene
Interventions
  • BEHAVIORAL
No Results Yet
NCT05886036 | RECRUITING | PHASE2
70 participants

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-05
Start Date:
2024-01-23
Completion:
2026-10-31
Conditions
  • Nodular Lymphocyte Predominant B-Cell Lymphoma
  • Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma
  • Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma
Interventions
  • PROCEDURE
  • OTHER
  • BIOLOGICAL
No Results Yet
NCT05812807 | RECRUITING | PHASE3
1295 participants

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-05
Start Date:
2023-06-14
Completion:
2033-05-31
Conditions
  • Anatomic Stage II Breast Cancer AJCC v8
  • Early Stage Triple-Negative Breast Carcinoma
  • Anatomic Stage IIIA Breast Cancer AJCC v8
  • Anatomic Stage IIIB Breast Cancer AJCC v8
Interventions
  • BIOLOGICAL
  • OTHER
  • PROCEDURE
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page